Stock Analysis
Medpace Holdings, Inc.MEDP
P/E 35.12×· 5Y range 20.77–48.17×· 71th percentile of history
Sector: Healthcare · Industry: Diagnostics & Research
AnalystsHold20 analystsP/E 35.1× sits at the 71st percentile of its 5.0513347022587265-year history.
No reported debt · FY 2023.
PMP Verdict
High quality, fairly valued
Strengths
- Quality90
- Growth80
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Altman Z 9.0 — safe-zone balance sheet
- ✓ROE 107.1% — efficient capital deployment
- ✓Revenue CAGR 22.0% — durable top-line growth
- ✓Interest coverage 139.9× — debt well covered
What's happening with MEDP
Profile
Strong earnings quality and growth; valuation lags behind.
How is each axis scored?
- Valuation39/100 · Weak
- P/E vs own history (71th pct)5/25
- FCF yield (4.1%)12/25
- P/S (6.2x)12/25
- EV/EBIT (n/a)10/25
- Growth80/100 · Strong
- Revenue CAGR (22.0%)25/25
- Net income CAGR (25.5%)25/25
- EPS CAGR 5Y (33.4%)25/25
- Fwd implied growth (4.6%)5/25
- Profitability65/100 · Moderate
- ROIC (n/a)0/25
- ROE (107.1%)25/25
- Net margin (17.7%)20/25
- Operating margin (21.0%)20/25
- Financial Health56/100 · Moderate
- Altman Z (8.98)25/25
- Current ratio (0.74)6/25
- Interest coverage (139.9x)25/25
- Net cash / debt (n/a)0/25
- Quality90/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-3.12)25/25
- FCF conversion (144%)25/25
- Margin stability (σ 2.8%)25/25
- Moat57/100 · Moderate
- ROIC >12% years (7/9 yrs)20/25
- Median gross margin (17.6%)0/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 3.2%)12/25
About Medpace Holdings, Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. Show more
It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Headquarters: CINCINNATI, OH · Employees: 6,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
39DP/E (TTM)35.1xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 20.8x–48.2x · 71st pct
P/FCF25.0xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.1%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.9%–6.4% · 36th pct
P/S (TTM)6.20xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.8x–7.8x · 74th pct
EV/EBITDA28.0xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral — vs own 5Y history: 20.3x–39.6x · 81st pct
EV/Sales6.2xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E33.6xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio37.60xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.97C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
65BROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE107.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA24.8%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.7%A
Grade A: HighNet Income / Revenue
Operating Margin21.0%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin21.0%D
Grade D: LowGross Profit / Revenue
FCF Margin25.4%A
Grade A: HighFCF / Revenue
True FCF Margin24.6%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
80ARevenue CAGR22.0%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR25.5%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)33.4%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth4.6%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-26.0%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income4.3%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.8%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
56CAltman Z-Score8.98A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.74xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.66xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage139.9xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
90A+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.12A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion143.8%A
Grade A: StrongFCF / Net Income
Margin Stability2.8%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue1.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.41xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
BURWIG SUSAN E Filed | BURWIG SUSAN E | Option exercise | -3000 | |
BURWIG SUSAN E Filed | BURWIG SUSAN E | Option exercise | +3.0K | |
BURWIG SUSAN E Filed | BURWIG SUSAN E | Option exercise | -2000 | |
BURWIG SUSAN E Filed | BURWIG SUSAN E | Option exercise | +2.0K | |
McCarthy Cornelius P. III Filed | McCarthy Cornelius P. III | Option exercise | -28 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
McCarthy Cornelius P. III Filed | McCarthy Cornelius P. III | Option exercise | +28 | |
Carley Brian T Filed | Carley Brian T | Option exercise | -36 | |
Carley Brian T Filed | Carley Brian T | Option exercise | +36 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
57CROIC >12% Years7/9 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)17.6%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor3.2%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$17.61
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$18.06
Cash & short-term investments per share (Finnhub)
Book Value / Share$15.58
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$497.05M
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$459.07M
Shareholders' equity (book value)
Asset / Liability1.30xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$17.26B
Current Market Capitalization
Beta1.11B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Medpace Holdings, Inc. (MEDP)
MEDP is down 1.61% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Medpace Holdings, Inc.. Altman Z-Score of 8.98 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.12 suggests a low likelihood of earnings manipulation.
- Revenue has compounded at roughly 22% annually, with net income growing about 26% per year — a strong growth profile.
- Medpace Holdings, Inc. converts about 25% of revenue into free cash flow — strong cash generation.
- Return on equity of 107.1% is well above the market average.
See how MEDP ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all MEDP moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | Regular | 622.33 | +3.81% | 2.26 |
| Oct 5 | After-hours | 620.51 | +3.51% | 2.08 |
| Oct 1 | Regular | 601.38 | -3.65% | -3.13 |
Frequently Asked Questions about MEDP
What is the current Medpace Holdings, Inc. (MEDP) stock price?
MEDP is trading at $618.47 at the last market close, down 1.61% on the session. PreMarketPrice tracks MEDP pre-market, intraday and after-hours prices.
Is MEDP stock a buy right now?
PreMarketPrice's quantitative model rates Medpace Holdings, Inc.'s financial health at 56/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is MEDP stock overvalued?
Medpace Holdings, Inc. trades at a trailing P/E of 35.1 and our valuation score rates it 39/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Medpace Holdings, Inc. report earnings?
No confirmed earnings date is currently scheduled for MEDP. The Earnings section lists recent reports and updates as dates are announced.
What sector does Medpace Holdings, Inc. operate in?
Medpace Holdings, Inc. operates in the Healthcare sector, within the Diagnostics & Research industry. The Related Stocks section lists sector peers for comparison.
What does Medpace Holdings, Inc. do?
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms.
About Medpace Holdings, Inc. (MEDP) Stock
Medpace Holdings, Inc. (MEDP) is a US-listed stock operating in the Healthcare sector, specifically the Diagnostics & Research industry. As of the latest update, Medpace Holdings, Inc. is trading at $618.47, down 1.61% on the day with a market capitalization of $17.3 billion. The financial health score for MEDP is 56/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for MEDP stock.
MEDP Stock Analysis & Key Metrics
On PreMarketPrice, you can track Medpace Holdings, Inc. (MEDP) across multiple dimensions:
- Pre-market price & movement: Real-time MEDP stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for MEDP with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Medpace Holdings, Inc. across multiple reporting periods.
- Financial health score: A composite score of 56/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for MEDP.
- Sector peers: Compare MEDP against 6 other healthcare stocks on key financial metrics.
Is MEDP a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Medpace Holdings, Inc. (MEDP) as an investment. The financial health score of 56/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Medpace Holdings, Inc. (MEDP) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.